Second-line hormonotherapy for breast cancer. Uselessness of first-line continuation.
The hypothesis that the results of second line hormonotherapy for breast cancer may be ameliorated with continuation of the first line has been explored in a randomized trial. Patients progressing under tamoxifen were randomly allocated to aminoglutethimide and hydrocortisone acetate with or without tamoxifen continuation. No difference has been observed between the two arms in terms of response rate and progression-free overall survival.
Pronzato
P
P
National Institute for Cancer Research, Genova, Italy.
Rubagotti
A
A
Amoroso
D
D
Bertelli
G
G
Queirolo
P
P
Sertoli
M R
MR
Rosso
M
M
Gallotti
P
P
Monzeglio
C
C
Rosso
R
R
D000368:Aged; D000616:Aminoglutethimide / Q000008:administration & dosage* / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy* / Q000473:pathology; D016019:Survival Analysis; D013629:Tamoxifen / Q000008:administration & dosage*
D013629:Tamoxifen; D000616:Aminoglutethimide; C021650:hydrocortisone acetate; D006854:Hydrocortisone